Thrombogenicity Assessment in Patients Treated With Bioresorbable Vascular Scaffolds

Withdrawn

• Conditions: Coronary Artery Disease
• Interventions: Device: Drug Eluting Stent; Device: Bioresorbable Vascular Scaffold

• Registration Number: NCT03033862
• Lead Sponsor: Inova Health Care Services

Brief Summary

Platelet activation and aggregation, intrinsic thrombogenicity, and biomarkers (fibrinogen, C-reactive protein, platelet endothelial cell adhesion molecule, von Willebrand factor, p-selectin) will be measured and compared following the implantation of Bioreabsorbable Vascular Scaffolds and Drug Eluting Stents.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-01-06
• Study First Submitted QC: 2017-01-24
• Study First Posted: 2017-01-27
• Study Start: 2017-07-01
• Primary Completion: 2017-07-01
• Study Completion: 2017-07-01
• Status Verified: 2018-08
• Last Update Submitted: 2020-06-12
• Last Update Posted: 2020-06-16

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Subject may be of either sex and of any race, and must be >18 years of age.
2. Subjects undergoing elective PCI due to de novo native coronary artery lesions (length ≤24 mm) with a reference vessel diameter of ≥2.5 mm and ≤3.75 mm.
3. Subject agrees to not participate in any other investigational or invasive clinical study for a period of 3 months following the index procedure.
4. Subject must be willing and able to give appropriate informed consent.
5. The subject is able to read and has signed and dated the informed consent document including authorization permitting release of personal health information approved by the investigator's Institutional Review Board (IRB).

Read More

Exclusion Criteria

• Hemodynamically unstable at the time of enrollment.

• Concurrent or anticipated treatment with warfarin (or derivatives, e.g., phenprocoumon), oral factor Xa inhibitor, or oral direct thrombin inhibitor after enrollment.

• GPI use prior to or at the time of PCI.

• History of a bleeding, or evidence of active abnormal bleeding.

• History at any time of intracranial hemorrhage, intracranial or spinal cord surgery, or a central nervous system tumor or aneurysm.

• Documented sustained severe hypertension (systolic blood pressure >200 mmHg or diastolic blood pressure >110 mmHg) at enrollment.

• Severe valvular heart disease, as defined by the American College of Cardiology /American Heart Association.

• History within 30 days before enrollment of invasive surgeries (other than mentioned above), or is anticipating one during the course of their study participation, or is planning to have one within 1 month post dosing with the study drug.

• History within 30 days before enrollment of TIA and ischemic (presumed thrombotic) stroke/CVA.

• Known platelet count <100,000/mm3 within 30 days before enrollment.

• Known active hepatobiliary disease, or known unexplained persistent increase in serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) activity to two times or more the upper limit of the reference range (upper limit of "normal" [↑2xULN]).

• Any serious medical comorbidity (e.g., active malignancy) such that the subject's life expectancy is <24 months.

• Known current substance abuse at the time of enrollment.

• Current participation in any other study of investigational therapy or participation in such a study within the last 30 days.

• Known hypersensitivity to any component of the current investigational product.

• Female subject of child-bearing potential.

• Subject is a woman who is breast-feeding.

• Subject is part of the staff personnel directly involved with this study or is a family member of the investigational staff.

• LVEF <30%

• Subject with known renal insufficiency with an estimated GFR <30 ml/min/1.73m or dialysis at the time of screening

• Subject requiring at least two lesion treatment and more suitable for staged PCI.

• Moderate or heavy calcification, tortuosity or other conditions are present proximal or within the target segment, reducing the likelihood that the Absorb BVS or XIENCE can be either delivered to or expanded at the lesion.

• Extreme angulation (≥90°) proximal to or within the target lesion.

• Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion.

• Lesion located within or distal to a diseased arterial graft or SVG.

• Aorto-ostial lesion (within 3 mm of the aorta junction).

• Lesion located in the left main artery.

• Lesion located within 2 mm of the origin of the LAD or LCX.

• Lesion involving a bifurcation with a:

  • side branch ≥ 2 mm in diameter, or
  • side branch with either an ostial or non-ostial lesion with diameter stenosis > 50%, or
  • side branch requiring dilatation.

• Target vessel contains thrombus.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Intervention with Drug Eluting Stent	Drug Eluting Stent	implant of drug eluting stent
Intervention with Bioresorbable Vascular Scaffold	Bioresorbable Vascular Scaffold	Implant of Abbott Bioresorbable stent

Primary Outcome Measures

Name	Time	Method
Change in Thrombogenicity from baseline after device implantation	60 Days	Platelet activation and aggregation, intrinsic thrombogenicity, and biomarkers will be measured at baseline and then reassessed at multiple time points after the implantation of the study device.

Trial Locations

Locations (1)

Inova Fairfax Hospital; 🇺🇸 Falls Church, Virginia, United States